Headlines about a drug "getting rejected by the FDA" often oversimplify what actually happened. For peptide drugs specifically, one of the most misunderstood regulatory events is the Complete Response Letter, a formal outcome that's more nuanced, and often more temporary, than it sounds.
What a Complete Response Letter Is
A Complete Response Letter, or CRL, is the FDA's formal way of telling a drug company that its application, whether a New Drug Application or a Biologics License Application, cannot be approved in its current form. The letter is required to describe the specific deficiencies the agency found, which can span a wide range of issues: unresolved safety or efficacy questions, problems with the clinical trial data itself, or manufacturing and facility inspection findings that have nothing to do with whether the drug works.
Why a CRL Isn't the Same as a Rejection
This distinction matters because a CRL doesn't necessarily mean a drug doesn't work or isn't safe, it can also reflect a fixable process or paperwork problem. A real, recent example involves insulin icodec, Novo Nordisk's once-weekly basal insulin peptide: the FDA issued a Complete Response Letter for the application, and the company subsequently resubmitted it after addressing the agency's concerns. The drug was ultimately approved and is now marketed as Awiqli, discussed elsewhere on this site in a head-to-head comparison with Eli Lilly's competing once-weekly insulin. That trajectory, initial CRL followed by resubmission and eventual approval, is common enough that it's worth understanding as one possible chapter in a drug's approval story rather than as its ending.
What Happens After a CRL
A company that receives a CRL generally has a few paths: resubmit the application after addressing the FDA's specific concerns (which can mean anything from providing additional data analysis to fixing manufacturing issues at a facility), request a meeting with the agency to clarify what's needed, formally dispute the decision, or in some cases abandon the application for that particular use. Resubmissions are themselves reviewed on a defined timeline (typically a few months for a focused resubmission, longer for one involving new clinical data), and there's no guarantee that a resubmission resolves the issue on the first attempt.
Why the Public Often Only Hears "Rejected"
Companies are required to disclose material regulatory events like CRLs to investors, but the specific deficiencies cited in a CRL are not always made fully public, since they can involve confidential manufacturing or trial-data details. That's part of why financial and trade press coverage of a CRL often reports the fact that one was issued, without being able to say precisely why, and why headlines can make an outcome sound more final than it turns out to be.
What This Means for Evaluating Peptide Drug News
When a peptide or other drug in this site's news coverage receives a CRL, the more useful question isn't just "did it get rejected," it's what kind of issue was cited, if that's been disclosed, and whether the company has indicated a resubmission timeline. A manufacturing-related CRL, for instance, is generally viewed very differently by drug-development analysts than one citing unresolved safety signals from clinical trial data.
The Bottom Line
A Complete Response Letter is a formal, specific regulatory tool, not a verdict on whether a drug is fundamentally safe or effective. Insulin icodec's own path from CRL to FDA approval as Awiqli is a concrete illustration that a CRL is often a step in a longer process rather than a final outcome.